TVP23C

Summary

TVP23C (trans-golgi network vesicle protein 23 homolog C, HGNC:30453) is a protein-coding gene on chromosome 17p12, encoding Golgi apparatus membrane protein TVP23 homolog C (Q96ET8).

Predicted to be involved in protein secretion and vesicle-mediated transport. Predicted to be located in membrane. Predicted to be active in Golgi membrane.

Source: NCBI Gene 201158 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 6 total — 2 pathogenic
• MANE Select transcript: NM_001135036

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30453
Approved symbol	TVP23C
Name	trans-golgi network vesicle protein 23 homolog C
Location	17p12
Locus type	gene with protein product
Status	Approved
Aliases	MGC8763
Ensembl gene	ENSG00000175106
Ensembl biotype	protein_coding
Entrez	201158

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000225576, ENST00000419890, ENST00000428082, ENST00000438826, ENST00000518321, ENST00000521179, ENST00000523573, ENST00000581273, ENST00000583206, ENST00000584811

RefSeq mRNA: 2 — MANE Select: NM_001135036 NM_001135036, NM_145301

CCDS: CCDS11170, CCDS45617

Canonical transcript exons

ENST00000518321 — 6 exons

Exon	Start	End
ENSE00002137998	15563437	15563483
ENSE00002715420	15536980	15540561
ENSE00003462785	15553685	15553829
ENSE00003549054	15545785	15545916
ENSE00003606380	15555282	15555364
ENSE00003679266	15547059	15547148

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 96.18.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0076 / max 1.9397, expressed in 1 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164691	0.9396	567
164692	0.0076	1

Top tissues by expression

229 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	96.18	gold quality
colonic epithelium	UBERON:0000397	91.83	gold quality
bone marrow cell	CL:0002092	90.04	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.28	gold quality
calcaneal tendon	UBERON:0003701	86.13	gold quality
adrenal tissue	UBERON:0018303	86.05	gold quality
lower esophagus mucosa	UBERON:0035834	84.01	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.10	gold quality
adenohypophysis	UBERON:0002196	82.96	gold quality
left ovary	UBERON:0002119	81.59	gold quality
islet of Langerhans	UBERON:0000006	81.51	gold quality
stromal cell of endometrium	CL:0002255	80.91	gold quality
pituitary gland	UBERON:0000007	80.82	gold quality
right uterine tube	UBERON:0001302	80.32	gold quality
right ovary	UBERON:0002118	80.15	gold quality
left lobe of thyroid gland	UBERON:0001120	80.11	gold quality
right lobe of thyroid gland	UBERON:0001119	79.58	gold quality
thyroid gland	UBERON:0002046	79.26	gold quality
ectocervix	UBERON:0012249	79.25	gold quality
endocervix	UBERON:0000458	79.15	gold quality
left adrenal gland cortex	UBERON:0035825	79.13	gold quality
body of uterus	UBERON:0009853	79.05	gold quality
uterine cervix	UBERON:0000002	78.84	gold quality
descending thoracic aorta	UBERON:0002345	78.82	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.80	gold quality
ascending aorta	UBERON:0001496	78.75	gold quality
popliteal artery	UBERON:0002250	78.67	gold quality
tibial artery	UBERON:0007610	78.67	gold quality
thoracic aorta	UBERON:0001515	78.62	gold quality
ganglionic eminence	UBERON:0004023	78.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting TVP23C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-6826-3P	98.19	66.32	1153
HSA-MIR-7111-3P	97.80	66.75	1467
HSA-MIR-4723-3P	97.67	65.91	1017
HSA-MIR-6769B-3P	97.41	65.53	1036
HSA-MIR-3183	97.40	65.68	978
HSA-MIR-10401-3P	91.66	66.01	97

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:112148	ENSDARG00000001804
danio_rerio	tvp23b	ENSDARG00000057060
mus_musculus	Tvp23b	ENSMUSG00000014177
rattus_norvegicus	AABR07006081.1	ENSRNOG00000016597
rattus_norvegicus	Tvp23b	ENSRNOG00000050649
drosophila_melanogaster	CG5021	FBGN0035944
caenorhabditis_elegans		WBGENE00016400

Paralogs (2): TVP23A (ENSG00000166676), TVP23B (ENSG00000171928)

Protein

Protein identifiers

Golgi apparatus membrane protein TVP23 homolog C — Q96ET8 (reviewed: Q96ET8)

All UniProt accessions (7): C9JPH1, C9JYS5, E5RGC5, E5RIS5, J3QL47, K7EK95, Q96ET8

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the TVP23 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96ET8-1	1	yes
Q96ET8-2	2
Q96ET8-3	3

RefSeq proteins (2): NP_001128508, NP_660344 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008564	TVP23-like	Family

Pfam: PF05832

UniProt features (16 total): sequence conflict 4, splice variant 4, transmembrane region 2, sequence variant 2, region of interest 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96ET8-F1	59.62	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 67 (showing top): chr17p12, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_SECRETION, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, FORTSCHEGGER_PHF8_TARGETS_DN, HMG20B_TARGET_GENES, NAB2_TARGET_GENES, MIR616_5P, MIR371B_5P, MIR373_5P, MIR548AJ_3P_MIR548X_3P, MIR548AE_3P_MIR548AQ_3P, MIR548AH_3P_MIR548AM_3P, MIR548J_3P, MIR3658

GO Biological Process (2): protein secretion (GO:0009306), vesicle-mediated transport (GO:0016192)

GO Molecular Function (0):

GO Cellular Component (2): Golgi membrane (GO:0000139), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein transport	1
secretion by cell	1
establishment of protein localization to extracellular region	1
protein localization to extracellular region	1
transport	1
cellular process	1
Golgi apparatus	1
bounding membrane of organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

366 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TVP23C	CDRT4	Q8N9R6	728
TVP23C	CDRT15	Q96T59	579
TVP23C	CCDC182	A6NF36	507
TVP23C	UBAP1L	F5GYI3	479
TVP23C	SMCO2	A6NFE2	447
TVP23C	TEKT3	Q9BXF9	418
TVP23C	RGPD1	P0C839	398
TVP23C	CFAP157	Q5JU67	396
TVP23C	TRMT13	Q9NUP7	378
TVP23C	MS4A14	Q96JA4	375
TVP23C	UEVLD	Q8IX04	370
TVP23C	KLHL28	Q9NXS3	370
TVP23C	ANKRD33B	A6NCL7	354
TVP23C	CEP95	Q96GE4	354
TVP23C	SREK1IP1	Q8N9Q2	349

IntAct

59 interactions, top by confidence:

A	B	Type	Score
RINT1	NBAS	psi-mi:“MI:0914”(association)	0.830
RANBP6	SLC27A2	psi-mi:“MI:0914”(association)	0.640
BZW2	ENDOD1	psi-mi:“MI:0914”(association)	0.640
TMEM9	ESYT2	psi-mi:“MI:0914”(association)	0.530
TOR1AIP2	TMEM223	psi-mi:“MI:0914”(association)	0.530
SLC7A1	TMEM223	psi-mi:“MI:0914”(association)	0.530
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
VSIG4	TCAF2	psi-mi:“MI:0914”(association)	0.530
SLC15A1	METTL15	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC2A12	METTL15	psi-mi:“MI:0914”(association)	0.530
TPCN2	AP3B1	psi-mi:“MI:0914”(association)	0.530
TSPAN5	SC5D	psi-mi:“MI:0914”(association)	0.530
ALOX5	DDHD2	psi-mi:“MI:0914”(association)	0.530
FUCA2	HSPA5	psi-mi:“MI:0914”(association)	0.530
TMEM63A	AP3D1	psi-mi:“MI:0914”(association)	0.530
	TMEM223	psi-mi:“MI:0914”(association)	0.350
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
TSPAN15	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC7A14	TMEM120B	psi-mi:“MI:0914”(association)	0.350
GPR17	TMEM120B	psi-mi:“MI:0914”(association)	0.350
LRRC55	TMEM120B	psi-mi:“MI:0914”(association)	0.350
ATP2A1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
C5AR1	TCAF2	psi-mi:“MI:0914”(association)	0.350
GPR182	METTL15	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
AQP3	RTL8C	psi-mi:“MI:0914”(association)	0.350
EDEM2	HACD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (75): TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-MS), TVP23C (Affinity Capture-RNA)

ESM2 similar proteins: A4Q9F3, A8IHN8, D3YYI7, M0R7T9, O09112, O60347, O88751, P51509, Q09YL6, Q0IHH1, Q13202, Q13505, Q14190, Q147X3, Q17QD9, Q3TZ87, Q3UPL5, Q3V1H9, Q5TGI4, Q5VUJ9, Q5VV17, Q5XI57, Q61079, Q6A039, Q6PDS0, Q6ZVT0, Q7Z7K6, Q80UW0, Q86YJ5, Q8C4U2, Q8CES0, Q8N554, Q8N8J7, Q8TC41, Q8TDR2, Q8WWW0, Q96AQ8, Q96ET8, Q96KN8, Q96MM7

Diamond homologs: A1CIM7, A1CW41, A2Q9P5, A3LRT4, A4RME3, A5DRE8, A6NH52, A6SFL7, A6ZY50, A7TGB4, A8N1Z1, B0CQN9, B0Y4Q8, B2ALT5, P38962, Q0CSZ7, Q0UV43, Q18449, Q1E9X9, Q29S14, Q2UUK2, Q4WQJ5, Q54LC9, Q5APA2, Q5R9I4, Q6BVH1, Q6C7V5, Q6CTK9, Q6FM91, Q74ZP5, Q7SGB6, Q8IQC1, Q8LEK2, Q96ET8, Q9D8T4, Q9NYZ1, Q9Y7K7, Q86I95, O14628, O94966

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 86 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
transport across blood-brain barrier	6	13.6×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

6 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	1
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1808684	GRCh37/hg19 17p12(chr17:14087934-15491532)x1	Pathogenic
523259	GRCh37/hg19 17p12(chr17:14215739-15422582)	Pathogenic

SpliceAI

1513 predictions. Top by Δscore:

Variant	Effect	Δscore
17:15540432:CTTGT:C	donor_gain	1.0000
17:15545777:ATACT:A	donor_loss	1.0000
17:15545779:AC:A	donor_loss	1.0000
17:15545780:CTCA:C	donor_loss	1.0000
17:15545781:TCAC:T	donor_loss	1.0000
17:15545782:C:CG	donor_loss	1.0000
17:15545782:CACCA:C	donor_loss	1.0000
17:15545783:A:AC	donor_gain	1.0000
17:15545783:A:T	donor_loss	1.0000
17:15545783:ACCAG:A	donor_gain	1.0000
17:15545784:C:A	donor_loss	1.0000
17:15545784:C:CC	donor_gain	1.0000
17:15545784:CCAGC:C	donor_gain	1.0000
17:15545828:A:AC	donor_gain	1.0000
17:15545914:CTC:C	acceptor_gain	1.0000
17:15545915:TC:T	acceptor_gain	1.0000
17:15545916:CC:C	acceptor_gain	1.0000
17:15545916:CCT:C	acceptor_loss	1.0000
17:15545916:CCTA:C	acceptor_loss	1.0000
17:15545917:C:A	acceptor_loss	1.0000
17:15545917:C:CC	acceptor_gain	1.0000
17:15545918:T:C	acceptor_loss	1.0000
17:15545918:T:G	acceptor_loss	1.0000
17:15547053:CTTTA:C	donor_loss	1.0000
17:15547054:TTTA:T	donor_loss	1.0000
17:15547055:TTA:T	donor_loss	1.0000
17:15547055:TTACC:T	donor_loss	1.0000
17:15547056:TACC:T	donor_loss	1.0000
17:15547058:CC:C	donor_loss	1.0000
17:15547058:CCT:C	donor_loss	1.0000

AlphaMissense

1344 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:15545866:A:C	F127L	0.972
17:15545866:A:T	F127L	0.972
17:15545868:A:G	F127L	0.972
17:15547071:A:C	F106L	0.971
17:15547071:A:T	F106L	0.971
17:15547073:A:G	F106L	0.971
17:15553685:C:A	K80N	0.969
17:15553685:C:G	K80N	0.969
17:15547115:A:G	W92R	0.966
17:15547115:A:T	W92R	0.966
17:15553787:A:C	S46R	0.964
17:15553787:A:T	S46R	0.964
17:15553789:T:G	S46R	0.964
17:15553697:A:C	F76L	0.963
17:15553697:A:T	F76L	0.963
17:15553699:A:G	F76L	0.963
17:15547077:C:A	W104C	0.944
17:15547077:C:G	W104C	0.944
17:15547146:A:C	N81K	0.944
17:15547146:A:T	N81K	0.944
17:15547079:A:G	W104R	0.938
17:15547079:A:T	W104R	0.938
17:15553700:G:C	D75E	0.936
17:15553700:G:T	D75E	0.936
17:15547110:C:A	W93C	0.933
17:15547110:C:G	W93C	0.933
17:15553701:T:A	D75V	0.930
17:15553796:A:C	F43L	0.929
17:15553796:A:T	F43L	0.929
17:15553798:A:G	F43L	0.929

dbSNP variants (sampled 300 via entrez): RS1000026878 (17:15515760 T>A,C), RS1000028694 (17:15561426 C>G), RS1000168876 (17:15535640 C>A), RS1000198754 (17:15510028 G>A), RS1000275774 (17:15541720 T>C), RS1000304485 (17:15535173 T>C), RS1000323685 (17:15554052 T>C), RS1000371847 (17:15504690 T>C), RS1000387972 (17:15548446 T>C), RS1000471990 (17:15506032 A>G), RS1000501315 (17:15536955 G>T), RS1000557553 (17:15518255 G>A), RS1000652500 (17:15509547 T>C,G), RS1000664393 (17:15542694 C>G,T), RS1000694686 (17:15502350 T>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (2): myopathy (MONDO:0005336), attention deficit-hyperactivity disorder (MONDO:0007743)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	decreases expression, increases expression	2
bisphenol F	affects cotreatment, decreases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
ferrous chloride	increases expression	1
arsenic disulfide	increases methylation	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
abrine	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenicals	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Dexamethasone	affects cotreatment, decreases expression	1
Indomethacin	decreases expression, affects cotreatment	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Tunicamycin	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	increases abundance, increases expression	1
Thapsigargin	increases expression	1
Okadaic Acid	increases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00120055	PHASE4	COMPLETED	Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity
NCT03633565	PHASE4	UNKNOWN	Comparative Study of Strategies for Management of Duchenne Myopathy (DM)
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00181571	PHASE4	COMPLETED	A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181675	PHASE4	COMPLETED	A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181714	PHASE4	COMPLETED	Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
NCT00181948	PHASE4	COMPLETED	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00181987	PHASE4	COMPLETED	Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder
NCT00190736	PHASE4	COMPLETED	Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190775	PHASE4	COMPLETED	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190879	PHASE4	COMPLETED	Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190957	PHASE4	COMPLETED	Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00191035	PHASE4	COMPLETED	Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191048	PHASE4	COMPLETED	Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191633	PHASE4	COMPLETED	Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00191906	PHASE4	COMPLETED	Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT00216918	PHASE4	COMPLETED	Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
NCT00221962	PHASE4	COMPLETED	Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
NCT00223561	PHASE4	COMPLETED	Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder
NCT00299234	PHASE4	TERMINATED	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
NCT00302406	PHASE4	COMPLETED	Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
NCT00305370	PHASE4	COMPLETED	Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
NCT00381758	PHASE4	COMPLETED	The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
NCT00406354	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00434213	PHASE4	COMPLETED	Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
NCT00468143	PHASE4	COMPLETED	A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
NCT00471354	PHASE4	COMPLETED	A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
NCT00483106	PHASE4	COMPLETED	Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
NCT00485849	PHASE4	COMPLETED	A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
NCT00485875	PHASE4	COMPLETED	Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
NCT00486122	PHASE4	COMPLETED	Evaluation of Continuous Symptom Treatment of ADHD
NCT00500071	PHASE4	COMPLETED	Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00506727	PHASE4	COMPLETED	Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD
NCT00510276	PHASE4	COMPLETED	Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
NCT00517504	PHASE4	COMPLETED	Methylphenidate Study in Young Children With Developmental Disorders
NCT00517647	PHASE4	COMPLETED	Atomoxetine Pilot Study in Preschool Children With ADHD
NCT00518232	PHASE4	COMPLETED	A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
NCT00530257	PHASE4	COMPLETED	Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
NCT00536419	PHASE4	UNKNOWN	Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents
NCT00546910	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)